Gilead Sciences (GILD) on Monday said it would acquire privately held Ouro Medicines, a biotech company developing T cell engager therapies for autoimmune diseases. The agreement includes $1.675 ...

This new type of immunotherapy shows promise for treating different cancers including prostate cancer, leukaemia and lung ...

When a virus enters the lungs, the immune system has to react fast. The lung maintains its own community of immune cells ...

Day-28 complete response occurred in 54/78 B-ALL patients, with MRD negativity in 83.3% of responders and median OS 13.6 ...

A new form of CAR T kills leukemia, multiple myeloma, and sarcoma in mice, opening the door to a future off-the-shelf cancer ...

Sanofi has returned to T-cell engager (TCE) territory via an agreement to pay $180 million in the near term for a phase ...

Scientists have built functional cancer-fighting immune cells directly inside living animals, skipping the expensive and time ...

Learn how KMA and LMA represent a breakthrough in treatment approaches for multiple myeloma and related disorders.

Gilead Sciences is paying $1.67 billion for a T-cell engager (TCE) company via a front-loaded deal that could also give new meaning to its partner Galapagos. By acquiring GSK-founded Ouro Medicines, ...

There are many different ways that doctors treat cancer, from chemotherapy to surgery. Another part of cancer treatment that ...

A protein already targeted by FDA-approved cancer drugs may also help the body fight influenza, according to new research ...